Eucrisa FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 28, 2021.
FDA Approved: Yes (First approved December 14, 2016)
Brand name: Eucrisa
Generic name: crisaborole
Dosage form: Topical Ointment
Company: Pfizer Inc.
Treatment for: Atopic Dermatitis
Eucrisa (crisaborole) is a phosphodiesterase 4 inhibitor indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
Development timeline for Eucrisa
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.